Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy
Decline in respiratory function in patients with DMD starts during early teenage years and leads to early morbidity and mortality. Published evidence of efficacy for idebenone on respiratory function outcomes is currently limited to 12 months of follow-up time. Here we report data collected as retro...
Egile Nagusiak: | Servais, L, Straathof, CSM, Schara, U, Klein, A, Leinonen, M, Hasham, S, Meier, T, De Waele, L, Gordish-Dressman, H, McDonald, CM, Mayer, OH, Voit, T, Mercuri, E, Buyse, GM |
---|---|
Formatua: | Journal article |
Hizkuntza: | English |
Argitaratua: |
Elsevier
2019
|
Antzeko izenburuak
Antzeko izenburuak
-
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
nork: Theodora Markati, et al.
Argitaratua: (2021-11-01) -
Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
nork: Marshall W. Hogarth, et al.
Argitaratua: (2017-01-01) -
Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
nork: Fatima Amor, et al.
Argitaratua: (2021-06-01) -
Duchenne Muscular Dystrophy
nork: J Gordon Millichap
Argitaratua: (1989-05-01) -
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
nork: Frank, DE, et al.
Argitaratua: (2020)